StreetInsider.com  Nov 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AspenBio+%28APPY%29+Closes+1.95M+Common+Offering/7895665.html for the full story.
StreetInsider.com  Oct 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AspenBio+%28APPY%29+Proposes+Corp.+Name+Change+to+%27Venaxis%27/7791224.html for the full story.
Benzinga  Sep 27  Comment 
AspenBio Pharma (Nasdaq: APPY), an in vitro diagnostic company, today provided its shareholders and the broader investment community with an update on its clinical and business activities.  The Company announced that it plans to initiate a...
Benzinga  Sep 18  Comment 
AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced that the United States District Court for Colorado has dismissed and entered judgment without prejudice in both the class action lawsuit (Case No....
Benzinga  Jul 30  Comment 
AspenBio Pharma, Inc. (Nasdaq: APPY) today announced that it has executed an exclusive worldwide license agreement with a major international animal health company, providing license and sub-license rights to AspenBio's entire animal health...
Benzinga  Jun 20  Comment 
AspenBio Pharma, Inc. (NASDAQ: APPY) yesterday announced the pricing of an underwritten public offering of 6,100,000 shares of common stock at an offering price of $2.00 per share. The number of shares and offering price reflect a one-for-six...
Benzinga  Dec 27  Comment 
AspenBio Pharma, Inc. (NASDAQ: APPY), announced today that it has entered into definitive agreements with certain new and existing institutional investors to sell an aggregate of 1,605,000 shares of its no par value common stock and warrants to...
StreetInsider.com  Oct 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AspenBio+%28APPY%29+Reports+BioMarker+Use+Improves+MRP+814+Results/6868718.html for the full story.
Benzinga  Oct 12  Comment 
AspenBio Pharma, Inc. (NASDAQ: APPY), today reported that the Company's Board of Directors has restructured AspenBio Pharma's governance to strategically focus the Company's resources in the most cost-effective manner, while retaining the...
Globe Newswire  Oct 2  Comment 
NEW YORK, Oct. 1, 2010 (GLOBE NEWSWIRE) -- The Rosen Law Firm today announced that it has filed a class action lawsuit on behalf of investors who purchased the common stock of AspenBio Pharma, Inc. ("AspenBio" or the "Company") (Nasdaq:APPY) between



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki